History
Documents created during the development process.
Background information
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: Appendix A - decision paper presented to the Institute's Guidance Executive
-
-
-
TA195 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: Appendix A provisional matrix of stakeholders
-
-
TA195 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: Appendix B proposal paper presented to the Institute's Guidance Executive
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: final appraisal determination
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: final appraisal determination
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: consultee and commentator comments on the ACD
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: additional analysis - supplementary data including a continuation rule as in Roche model
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: manufacturer/sponsor
-
Abbott
-
-
Bristol-Myers Squibb
-
-
Roche
-
-
Schering-Plough (confidential information, including appendix 3, removed)
-
Schering-Plough (confidential information, including appendix 3, removed) (PDF 276 KB)
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: professional and patient groups
-
Arthritis Care
-
-
Arthritis and Musculoskeletal Alliance
-
-
Arthritis Research
-
-
British Health Professionals in Rheumatology
-
-
British Society for Rheumatology
-
-
National Rheumatoid Arthritis Society
-
-
National Rheumatoid Arthritis Society - appendix 1
-
National Rheumatoid Arthritis Society - appendix 1 (PDF 63 KB)
-
Royal College of Nursing
-
-
Royal College of Physicians
-
-
Royal College of Pathologists
-
-
Department of Health
-
-
NHS Quality Improvement Scotland
-
-
UCB
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: comments from website consultation
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: appraisal consultation document
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: appraisal consultation document
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: evaluation report
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: assessment report
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: overview
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: addendum to the Assessment Report
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: correction to the Addendum Report
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: consultee and commentator comments on the assessment report
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: consultee and commentator comments on the assessment report - Abbott
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: consultee and commentator comments on the assessment report - Arthritis and Musculoskeletal Alliance
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: consultee and commentator comments on the assessment report - Bristol-Myers Squibb
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: consultee and commentator comments on the assessment report - British Society For Rheumatology
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: consultee and commentator comments on the assessment report - Department of Health
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: consultee and commentator comments on the assessment report - National Rheumatoid Arthritis Society
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: consultee and commentator comments on the assessment report - NHS Quality Improvement Scotland
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: consultee and commentator comments on the assessment report - Roche Products
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: consultee and commentator comments on the assessment report - Royal College of Nursing
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: consultee and commentator comments on the assessment report - Royal College of Physicians
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: consultee and commentator comments on the assessment report - Schering-Plough
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: consultee and commentator comments on the assessment report - UCB Pharma
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: consultee and commentator comments on the assessment report - Wyeth
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: non-manufacturer submissions
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: non-manufacturer submission - Arthritis and Musculoskeletal Alliance
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: non-manufacturer submission - British Health Professionals in Rheumatology
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: non-manufacturer submission - British Society For Rheumatology
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: non-manufacturer submission - National Rheumatoid Arthritis Society
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: non-manufacturer submission - Royal College of Nursing
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: non-manufacturer submission - Royal College of Physicians
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: manufacturer submissions
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: manufacturer submission - Abbott
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: manufacturer submission - Bristol-Myers Squibb
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: manufacturer submission - Roche
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: manufacturer submission - Schering-Plough
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: manufacturer submission - Wyeth
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: expert written personal statements
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: expert written personal statements - McKenna
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: expert written personal statements - Deighton
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: expert written personal statements - Bosworth
-
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: expert written personal statements - Burke
-
Drugs for the treatment of rheumatoid arthritis (after the failure of TNF inhibitor): assessment report
-
Drugs for the treatment of rheumatoid arthritis (after the failure of TNF inhibitor): assessment report
-
Drugs for the treatment of rheumatoid arthritis (after the failure of TNF inhibitor): final scope
-
Drugs for the treatment of rheumatoid arthritis (after the failure of TNF inhibitor): final scope
-
Drugs for the treatment of rheumatoid arthritis (after the failure of TNF inhibitor): final matrix of consultees and commentators
-
Drugs for the treatment of rheumatoid arthritis (after the failure of TNF inhibitor): final matrix of consultees and commentators
-
Drugs for the treatment of rheumatoid arthritis (after the failure of TNF inhibitor): comments on the draft scope and provisional matrix
-
Drugs for the treatment of rheumatoid arthritis (after the failure of TNF inhibitor): comments on the draft scope and provisional matrix
-
Drugs for the treatment of rheumatoid arthritis (after the failure of a TNF inhibitor): draft scope
-
Drugs for the treatment of rheumatoid arthritis (after the failure of a TNF inhibitor): draft scope
-
Drugs for the treatment of rheumatoid arthritis (after the failure of a TNF inhibitor): provisional matrix of consultees
-
Drugs for the treatment of rheumatoid arthritis (after the failure of a TNF inhibitor): provisional matrix of consultees
-